NDAORALTABLET
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
FROVA (frovatriptan succinate) by Leadingtac Pharmaceutical is 5-ht 1b/1d receptors. Approved for migraine attacks, cluster headache, migraine. First approved in 2001.
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FROVA (frovatriptan succinate) is an oral triptan approved in 2001 for acute migraine and cluster headache treatment. It works as a selective 5-HT1B/1D receptor agonist, causing cranial vasoconstriction and blocking pro-inflammatory neuropeptide release in the trigeminal system.
$0.357MPart D
LOE ApproachingDeclining
Minimal Part D penetration ($357K, 138 claims in 2023) signals a niche product with declining commercial activity as loss of exclusivity approaches, requiring lean commercial teams focused on retention.
Mechanism of Action
5-HT 1B/1D receptors. The therapeutic activity of frovatriptan succinate is thought to be due to the agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel…
Indications (3)
Worked on FROVA at Leadingtac Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.